Good morning :)
Aarti Pharmalabs Ltd

Aarti Pharmalabs Ltd

AARTIPHARM Share Price

NSE
820.401.04% (-8.60)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹7,439 cr, stock is ranked 708

Stock is 3.37x as volatile as Nifty

AARTIPHARM Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹7,439 cr, stock is ranked 708

Stock is 3.37x as volatile as Nifty

AARTIPHARM Performance & Key Metrics

AARTIPHARM Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
34.913.500.43%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
47.205.920.48%

AARTIPHARM Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
0%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

AARTIPHARM Company Profile

Aarti Pharmalabs Ltd manufactures active pharmaceutical ingredients and intermediates, offering CDMO services for drug development and production, with a focus on oncology and corticosteroid products.

Investor Presentation

View older View older 

Aug 10, 2026

PDF
View Older Presentations

AARTIPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 

AARTIPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
96.91
96.91
1Y Return
53.39%
53.39%
Buy Reco %
60.87
60.87
PE Ratio
46.83
46.83
1Y Return
43.91%
43.91%
Buy Reco %
62.50
62.50
PE Ratio
34.78
34.78
1Y Return
23.71%
23.71%
Buy Reco %
0.00
0.00
PE Ratio
27.43
27.43
1Y Return
40.47%
40.47%
Buy Reco %
0.00
0.00
PE Ratio
46.77
46.77
1Y Return
33.79%
33.79%
Buy Reco %
0.00
0.00
Compare with Peers

AARTIPHARM Sentiment Analysis

AARTIPHARM Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

AARTIPHARM Stock Summary · August 2026

Management struck a constructive but measured tone, saying the quarter was led by sharp year-over-year growth in revenue, EBITDA and PAT, with record xanthine sales as the biggest driver. Xanthine volumes rose about 25% and the business remained heavily export-oriented at 79% of revenue, supported by recent capacity additions and pricing that stayed above pre-war levels even as it eased from peak levels. At the same time, management noted that raw-material pass-through makes xanthine margin guidance difficult and that API and intermediates continued to face pricing pressure, partly offset by cost-reduction work and new launches ahead. The CDMO/CMO business, which contributed 7% of quarterly revenue, remained weighted to the second half, with 22 customers and 57 active projects, and management reiterated FY27 growth guidance of 40% to 50% alongside a broader ambition of INR1,000 crore in revenue. Capacity expansion remained a priority, including new dedicated blocks and brownfield buildouts, while management reaffirmed company EBITDA margin guidance of 20% to 25%, standalone FY27 margins of 22% to 25%, and xanthine revenue of INR900 crore to INR1,100 crore for the year.

AARTIPHARM Stock Growth Drivers
AARTIPHARM Stock Growth Drivers
8
  • Strong Consolidated Earnings Growth

    The company delivered a very strong standalone Q1 FY27 performance, with revenue rising to INR535

  • Xanthine Franchise Momentum and Pricing Tailwinds

    The Xanthine derivatives business emerged as a standout growth driver, contributing 57% of turnover and

AARTIPHARM Stock Challenges
AARTIPHARM Stock Challenges
5
  • Xanthine Pricing Pressure and Margin Volatility

    Xanthine realizations have weakened from peak conflict-period levels and are now moving lower with raw

  • Heavy Dependence on China-Centered Competition in Xanthine

    The Xanthine market remains overwhelmingly dominated by China-based competitors, with management estimating that roughly 80%

AARTIPHARM Forecast

AARTIPHARM Forecasts

Price

Revenue

Earnings

AARTIPHARM

AARTIPHARM

Income

Balance Sheet

Cash Flow

AARTIPHARM Income Statement

AARTIPHARM Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue507.80557.71462.51542.81562.17387.79418.39436.83596.21543.66
Operating & Other expensessubtract388.25459.03364.35409.17418.15292.74344.26332.76469.51399.69
Depreciation/Amortizationsubtract19.1220.1720.8823.0422.8222.7924.7728.6228.1630.03
Interest & Other Itemssubtract4.684.835.519.976.586.7910.6712.5816.8612.88
Taxes & Other Itemssubtract30.5018.2317.1426.6426.2715.9510.7714.9220.5624.92
EPS7.206.126.038.169.755.463.085.296.748.40

AARTIPHARM Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Aug 10PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 26PDF
Feb 10PDF
Nov 11PDF
+2 more
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 12PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Sep 14PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Jun 26PDF
 

AARTIPHARM Stock Peers

AARTIPHARM Past Performance & Peer Comparison

AARTIPHARM Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aarti Pharmalabs Ltd42.593.500.43%
Divi's Laboratories Ltd96.9114.850.32%
Syngene International Ltd46.833.070.34%
Vimta Labs Ltd34.785.900.33%

AARTIPHARM Stock Price Comparison

Compare AARTIPHARM with any stock or ETF
Compare AARTIPHARM with any stock or ETF
AARTIPHARM
Loading...

AARTIPHARM Holdings

AARTIPHARM Shareholdings

AARTIPHARM Promoter Holdings Trend

AARTIPHARM Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

AARTIPHARM Institutional Holdings Trend

AARTIPHARM Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

AARTIPHARM Shareholding Pattern

AARTIPHARM Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.86%0.79%6.43%8.17%41.74%

Sep 2025

Dec 2025

Mar 2026

Jun 2026

AARTIPHARM Shareholding History

AARTIPHARM Shareholding History

MarJunSepDec '25MarJun7.36%7.35%8.02%7.68%8.39%8.17%

Mutual Funds Invested in AARTIPHARM

Mutual Funds Invested in AARTIPHARM

No mutual funds holding trends are available

Top 5 Mutual Funds holding Aarti Pharmalabs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.1705%0.88%0.10%41/46 (-1)
0.1520%0.45%0.06%53/256 (+28)
0.1330%1.10%0.24%25/72 (+22)

Compare 3-month MF holding change on Screener

AARTIPHARM Insider Trades & Bulk Stock Deals

AARTIPHARM Insider Trades & Bulk Stock Deals

Loading...

smallcases containing AARTIPHARM stock

smallcases containing AARTIPHARM stock

Looks like this stock is not in any smallcase yet.

AARTIPHARM Events

AARTIPHARM Events

AARTIPHARM Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

AARTIPHARM Dividend Trend

No dividend trend available

AARTIPHARM Upcoming Dividends

AARTIPHARM Upcoming Dividends

No upcoming dividends are available

AARTIPHARM Past Dividends

AARTIPHARM Past Dividends

Cash Dividend

Ex DateEx DateSep 15, 2026

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Sep 15, 2026

Cash Dividend

Ex DateEx DateFeb 16, 2026

Interim
Interim | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Feb 16, 2026

Cash Dividend

Ex DateEx DateSep 15, 2025

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 15, 2025

Cash Dividend

Ex DateEx DateFeb 14, 2025

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Feb 14, 2025

Cash Dividend

Ex DateEx DateJul 31, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Jul 31, 2024

AARTIPHARM Stock News & Opinions

AARTIPHARM Stock News & Opinions

Corporate
Corporate
Aarti Pharma Labs announced the resignation of G.M. Naidu, effective August 31, 2026

Aarti Pharma Labs informed the BSE and National Stock Exchange of India that G.M. Naidu, Manufacturing/Sr. General Manager and Senior Management Personnel, resigned from his position, effective August 31, 2026, due to personal commitments.

2 weeks agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs sets record date for final dividend payment of Rs 2.00 per share

Aarti Pharmalabs Limited has set September 15, 2026, as the record date for the payment of a final dividend of Rs 2.00 per equity share, representing 40% of the Rs 5 face value, for the financial year 2025-26, subject to shareholder approval at the Annual General Meeting scheduled for September 22, 2026, with payment expected on or before October 20, 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Aarti Pharmalabs Ltd leads gainers in 'A' group

Hitachi Energy India Ltd, Sky Gold & Diamonds Ltd, One 97 Communications Ltd and Poly Medicure Ltd are among the other gainers in the BSE's 'A' group today, 10 August 2026.Aarti Pharmalabs Ltd spiked 20.00% to Rs 821.45 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.08 lakh shares were traded on the counter so far as against the average daily volumes of 7739 shares in the past one month. Hitachi Energy India Ltd soared 10.31% to Rs 35938. The stock was the second biggest gainer in 'A' group. On the BSE, 38776 shares were traded on the counter so far as against the average daily volumes of 7711 shares in the past one month. Sky Gold & Diamonds Ltd surged 8.04% to Rs 774.55. The stock was the third biggest gainer in 'A' group. On the BSE, 2.5 lakh shares were traded on the counter so far as against the average daily volumes of 71210 shares in the past one month. One 97 Communications Ltd advanced 7.91% to Rs 1555. The stock was the fourth biggest gainer in 'A' group. On the BSE, 4.77 lakh shares were traded on the counter so far as against the average daily volumes of 3.21 lakh shares in the past one month. Poly Medicure Ltd exploded 6.50% to Rs 1802.3. The stock was the fifth biggest gainer in 'A' group. On the BSE, 69567 shares were traded on the counter so far as against the average daily volumes of 6610 shares in the past one month.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs director Rajendra Gogri will retire at the upcoming AGM

Aarti Pharmalabs Limited informed the Bombay Stock Exchange and National Stock Exchange of India that Rajendra Vallabhaji Gogri, a Non-Executive Director and liable to retire by rotation at the upcoming Annual General Meeting, will not seek re-appointment due to personal goals and other commitments, concluding his tenure as Director at the close of business hours of the ensuing AGM.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs announces board meeting date

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 7 August 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs allots 22,062 equity shares under ESOP

Aarti Pharmalabs has allotted 22,062 equity shares under ESOP on 25 June 2026. Post this allotment, the paid-up Equity share capital of the Company stands increased to Rs. 45,33,99,065 representing 9,06,79,813 fully paid-up equity shares of face value of Rs.5/- each.

2 months agoCapital Market - Live
Corporate
Corporate
Board of Aarti Pharmalabs recommends final dividend

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held on 25 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 40%) , subject to the approval of the shareholders.

3 months agoCapital Market - Live
Earnings
Earnings
Aarti Pharmalabs consolidated net profit declines 30.81% in the March 2026 quarter

Net profit of Aarti Pharmalabs declined 30.81% to Rs 61.12 crore in the quarter ended March 2026 as against Rs 88.34 crore during the previous quarter ended March 2025. Sales rose 3.35% to Rs 582.64 crore in the quarter ended March 2026 as against Rs 563.78 crore during the previous quarter ended March 2025. For the full year,net profit declined 35.86% to Rs 174.71 crore in the year ended March 2026 as against Rs 272.40 crore during the previous year ended March 2025. Sales declined 13.98% to Rs 1819.44 crore in the year ended March 2026 as against Rs 2115.07 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales582.64563.78 3 1819.442115.07 -14 OPM %19.4225.83 -20.2921.96 - PBDT109.83137.44 -20 340.05447.59 -24 PBT81.68114.62 -29 235.71360.69 -35 NP61.1288.34 -31 174.71272.40 -36 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs revises board meeting date

Aarti Pharmalabs has revised the meeting of the Board of Directors which was scheduled to be held on 18 May 2026. The meeting will now be held on 25 May 2026.

4 months agoCapital Market - Live
Corporate
Corporate
Aarti Pharmalabs announces board meeting date

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 18 May 2026.

4 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. The share price of AARTIPHARM as on 18th September 2026 is ₹820.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Aarti Pharmalabs Ltd (AARTIPHARM) share are
    • Past 1 week: 0.20%
    • Past 1 month: -4.52%
    • Past 3 months: 24.59%
    • Past 6 months: 25.05%
    • Past 1 year: -8.87%
    • Past 3 years: 79.85%
    • Past 5 years: 184.61%

  3. The current dividend yield of Aarti Pharmalabs Ltd (AARTIPHARM) is 0.43.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹7439.37 Cr as of 18th September 2026.

  5. The 52-week high of Aarti Pharmalabs Ltd (AARTIPHARM) is ₹940.50 and the 52-week low is ₹585.

  6. The P/E (price-to-earnings) ratio of Aarti Pharmalabs Ltd (AARTIPHARM) is 42.59. The P/B (price-to-book) ratio is 3.50.

  7. Aarti Pharmalabs Ltd (AARTIPHARM) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

  8. You can directly buy Aarti Pharmalabs Ltd (AARTIPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.